Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

patient experience

Case study: How we iteratively tested and refined payer value messages

Find out how we helped our client to enrich their understanding of the value message trade-off choices and preferences made by payers

Research Partnership

- PMLiVE

Medscape Education and Medics4RareDisease Uncover the Education Gaps in Their Compelling Rare Disease Day Campaign

Medscape Education and Medics4RareDisease are partnering on a Rare Disease Day awareness campaign. The campaign will form part of a series of short programs produced by ITN in collaboration with Genetic Alliance...

Medscape Education Global

- PMLiVE

5 ways we’re enhancing our services to support our clients in 2023

Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.

Avalere Health

- PMLiVE

Report gives insights to address gaps in HCP engagement

How does Pharma-HCP engagement need to evolve in today's digital landscape?

EPG Health

- PMLiVE

Takeda therapy shows promise in rare blood clotting disorder

Phase 3 results show the enzyme replacement therapy reduced thrombocytopenia events by 60%

- PMLiVE

Pfizer announces positive phase 3 results for haemophilia B gene therapy

A one-off, intravenous dose of the therapy candidate reduced bleeding by 71%

Mike Bushell presenting PMEA award to two Bedrock employees

Bedrock Healthcare Communications is proud to accept the PMEA for Agility in Pharma Market Excellence

Recognition for a bold and imaginative approach to an actionable clinical consensus for MS patients.

Bedrock Healthcare Communications

How to tell a better silent story

How To Tell A Better Silent Story

They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story.

The Good Ideas Group

- PMLiVE

Sarepta to assess imlifidase as pre-treatment to Duchenne muscular dystrophy gene therapy

The company submitted a Biologics License Application to the FDA for SRP-9001 in September

Cell and gene therapies as depicted via a DNA strand

The fast-paced future of cell and gene therapies

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...

Avalere Health

- PMLiVE

FDA receives Santhera and ReveraGen’s application for Duchenne muscular dystrophy treatment

The submission includes positive data from the pivotal phase 2b and four open-label studies

Biomarin

BioMarin’s application for haemophilia A gene therapy accepted by FDA

If approved, the treatment would be the first gene therapy in the US for this indication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links